FDA approvals of atopic dermatitis, nasolabial fold treatments top dermatology reads for week

The FDA’s approval of Eucrisa for atopic dermatitis and Restylane dermal fillers for nasolabial folds were among the most-read articles of the past week on Healio.com/Dermatology.

Other widely read articles included research showing that Taltz treatment for psoriasis, including maintenance up to 60 weeks, had an acceptable safety profile with no unexpected safety findings:

FDA approves Eucrisa for atopic dermatitis

The FDA announced it has approved Eucrisa ointment to treat mild-to-moderate atopic dermatitis in patients aged 2 years and older.

Eucrisa (crisaborole; Pfizer) is a phosphodiesterase 4 inhibitor, which is to be applied twice daily, although its specific mechanism in atopic dermatitis is unknown, according to the release. Read more

New methods to evaluate wound healing reviewed

Although nontraditional methods have been developed to measure wound healing, there is no gold standard method for evaluation, according to a review article published in Dermatologic Surgery.

The authors from Thailand reviewed research on nontraditional techniques to evaluate wound healing, with the techniques divided into five categories based on their measured outcome. Read more

FDA approves Restylane dermal fillers for treating nasolabial folds

Galderma announced it has received FDA approval of two new Restylane products for the treatment of nasolabial folds in patients over the age of 21.

The agency approved Restylane Refyne for moderate-to-severe facial wrinkles and folds and Restylane Defyne for treating moderate-to-severe, deep facial wrinkles and folds. Read more

Taltz maintenance in psoriasis shows acceptable safety profile

Taltz treatment for psoriasis, including maintenance up to 60 weeks, had an acceptable safety profile with no unexpected safety findings, according to a published analysis of seven clinical trials.

Bruce Strober, MD, PhD, professor of dermatology, director of clinical trials and chair of the dermatology department at University of Connecticut Health Center and Probity Medical Research, and colleagues conducted an integrated safety profile of seven clinical trials involving Taltz (ixekizumab, Eli Lilly) in patients with psoriasis. UNCOVER-1, UNCOVER-2 and UNCOVER-3 placebo-controlled phase 3 trials of ixekizumab were the main data sources. Read more

Psoriasis associated with risk for avascular necrosis

Patients with psoriasis had a significant risk for avascular necrosis, which increased with disease severity of psoriasis, according to study results recently published in the Journal of the American Academy of Dermatology.

Researchers identified 28,268 outpatients and inpatients (mean age, 46.12 years) with new-onset psoriasis diagnosed between 2004 and 2006 using data from the Taiwan National Health Insurance Research Database. Read more